RenovaCare Inc (OTCMKTS:RCAR) has been powering in an uptrend as traders digest the impact of the company’s recent press on the potentially revolutionary impact of its lead product, the SkinGun. In articles published in Women’s Weekly, Huffington Post, and BioScience Technology, the product received very prominent treatment. This came just a couple weeks after the company announced the appointment of Roger Esteban-Vives, Ph.D. as Director of Cell Sciences.
“I’m thrilled to be joining the RenovaCare team to help bring to market the company’s breakthrough stem cell spray technology, the SkinGun™,” said Dr. Roger Esteban-Vives. “What makes the SkinGun unique is its ability to gently spray large areas of wounds and burns with a patient’s own stem cells, within only minutes of arriving in an emergency ward. Best of all, the process is entirely natural, quick, and gentle.”
RenovaCare Inc (OTCMKTS:RCAR) promulgates itself as a company that focuses on the acquisition, research, development, and commercialization of autologous cellular therapies for use in medical and aesthetic applications.
It develops a treatment methodology for skin isolation; and SkinGun, a medical-grade liquid spraying device and associated equipment for the regeneration of human skin cells. The company was formerly known as Janus Resources, Inc. and changed its name to RenovaCare, Inc. in January 2014. RenovaCare, Inc. is based in New York, New York.
According to company materials, “RenovaCare, Inc. is developing first-of-its-kind autologous stem cell therapies for the regeneration of human organs. Its initial product under development targets the body’s largest organ, the skin. The company’s flagship technology, the CellMist™ System, uses its patented SkinGun™ to spray a liquid suspension of a patient’s stem cells – the CellMist™ Solution – onto wounds. RenovaCare is developing its CellMist™ System as a promising new alternative for patients suffering from burns, chronic and acute wounds, and scars. In the US alone, this $45 billion market is greater than the spending on high-blood pressure management, cholesterol treatments, and back pain therapeutics.”
Find out when $RCAR stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
The company has been putting the pedal to the metal lately as far as generating greater exposure for its product.
According to their materials, “RenovaCare is developing its patented SkinGun to spray a liquid suspension of a patient’s stem cells – the CellMist Solution – onto wounds. RenovaCare believes the technology will be a promising new alternative for patients suffering from burns, chronic and acute wounds, and scars. In the U.S. alone, this $45 billion market is greater than the spending on high-blood pressure management, cholesterol treatments, and back pain therapeutics. Key to the RenovaCare approach is its ultra-gentle delivery of regenerative stem cells to the wound site. The company’s SkinGun™ achieves uniform distribution of fluids with 200 times greater coverage than conventional methods, according to tests conducted at Stem cell Systems GmbH (Berlin, Germany).”
We’ve witnessed just under 110% during the past week in terms of shareholder gains in the listing, but that move comes in the context of a larger bearish trend. Market participants may want to pay attention to this stock. RCAR has a history of dramatic rallies. What’s more, the name has seen a recent influx of interest, with the stock’s recent average trading volume running 500% beyond what we have been seeing over the larger time frame.
It pays to take note of this fact due to the limited float size in the stock (just a tad more than 20M shares). Traders should not overlook this combination, as a jump in average daily transaction volume in a stock with a restricted float can unleash fireworks as supply is squeezed.
Currently trading at a market capitalization of $145.5M, RCAR has a decent store ($687.75k) of cash on the books, with total assets greater than $850K, which compares with very little total accumulated debt.
The exposure is great and the company can certainly benefit. However, eventually this will likely have to reconciled with government oversight on some level, and we will see this product put to the test. For now, however, this is a very interesting story generating a lot of excitement. We will update again soon as events dictate. For continuing coverage on shares of $RCAR stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!